Grifols, a producer of plasma-derived medicines, entered a global collaboration and licensing agreement with Selagine Inc, a company focused on developing novel therapeutics for ocular diseases, to treat dry eye disease (DED) with immunoglobulin eye drops.   The potential Ig treatment, following clinical development and regulatory authorizations, would become Grifols’ first ocular-surface indicated medicine as well as the company’s first-ever product for DED, which affects more than 100 millio...